.
British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukaemia(MLL) - the most common form of leukaemia in babies.
In a study published in the journal Nature, scientists from the British drug maker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukaemia genes.
To read the full story click HERE.
.
No comments:
Post a Comment